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BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are often found in tumours, presumably reflecting an immune response against
the tumour. We carried out a systematic review and meta-analysis, aiming to establish pooled estimates for survival outcomes based
on the presence of TILs in cancer.
METHODS: A Pubmed and Embase literature search was designed. Studies were included, in which the prognostic significance of
intratumoural CD3þ, CD4þ, CD8þ, and FoxP3þ lymphocytes, as well as ratios between these subsets, were determined in
solid tumours.
RESULTS: In pooled analysis, CD3þ TILs had a positive effect on survival with a hazard ratio (HR) of 0.58 (95% confidence interval (CI)
0.43–0.78) for death, as did CD8þ TILs with a HR of 0.71 (95% CI 0.62–0.82). FoxP3þ regulatory TILs were not linked to overall
survival, with a HR of 1.19 (95% CI 0.84–1.67). The CD8/FoxP3 ratio produced a more impressive HR (risk of death: HR 0.48, 95%
CI 0.34–0.68), but was used in relatively few studies. Sample size and follow-up time seemed to influence study outcomes.
CONCLUSION: Any future studies should be carefully designed, to prevent overestimating the effect of TILs on prognosis. In this
context, ratios between TIL subsets may be more informative.
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Tumour infiltrating lymphocytes (TILs) are frequently found in
tumours, suggesting that tumours trigger an immune response in
the host. This so-called tumour immunogenicity is mediated by
tumour antigens. These antigens distinguish the tumour from
healthy cells, thereby providing an immunological stimulus (Boon
et al, 1997).
The concept of ‘cancer immunoediting’ describes how the
immune system and tumour cells interact during the course of
cancer development. It consists of three distinct phases, termed
‘the three E’s’ (Kim et al, 2007). Elimination entails the complete
obliteration of tumour cells by T lymphocytes. In equilibrium, a
population of immune-resistant tumour cells appears. Simulta-
neously, there is an unremitting immunological pressure on non-
resistant tumour cells. This phase can last for years (Kim et al,
2007). Finally, during escape, the tumour has developed strategies
to evade immune detection or destruction. These may be loss of
tumour antigens, secretion of inhibitory cytokines, or down-
regulation of major histocompatibility complex molecules (Stewart
and Abrams, 2008). Additionally, antigens may be ineffectively
presented to the immune system, that is, without appropriate
co-stimulation, resulting in immunological tolerance (Stewart and
Abrams, 2008).
Many studies report a survival benefit associated with the
presence of TIL (Zhang et al, 2003; Sato et al, 2005; Galon et al,
2006; Leffers et al, 2009). This suggests that TILs are effective at
delaying tumour progression, despite being antagonised by the
mechanisms mentioned above. However, it is important to
distinguish between different types of T lymphocytes, because
they all have different functions in the tumour microenvironment.
CD8þ cytotoxic T lymphocytes (CTLs) are directly capable of
killing tumour cells. CD4þ T helper lymphocytes (Th) are a
heterogeneous cytokine secreting class of T lymphocytes. T helper
type 1 lymphocytes (Th1) have a crucial role in activating CTLs.
T helper type 2 lymphocytes stimulate humoral immunity and
activate eosinophils. In terms of antitumour immunity, Th2
activation is less effective than Th1 activation (Yu and Fu, 2006).
Besides the Th1 and Th2 subsets, a CD4þ regulatory
T lymphocyte (Treg) subset suppresses effector T lymphocytes
(Curiel et al, 2004). In cancer, Treg preferentially traffic to
tumours, as a result of chemokines produced by tumour cells and
microenvironmental macrophages (Curiel et al, 2004). In recent
years, the hypothesis that ratios between different subsets are most
predictive of prognosis has gained much attention. Frequently
used ratios are CD8þ/FoxP3þ (effector:regulatory) ratio and
CD8þ/CD4þ (effector:helper) ratio. These measures may
provide a more comprehensive view of the events at the site of
disease, as the immune system is not a collection of solitary agents,
but rather a complex system of checks and balances – each subset
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sbeing dependent upon collaboration with and authorisation from
other subsets.
A commonly used approach to gain more insight in the in vivo
interaction between tumours and the immune system is to quantify
the numbers of TILs, and to relate these to tumour characteristics
and prognostic outcome. These studies have been carried out
across many types of cancer, and many types of TIL, with widely
differing sample sizes. We were interested in obtaining a more
precise estimate of the effect of TIL on survival. Therefore, we
undertook a systematic review and meta-analysis, aiming to
establish pooled estimates for survival outcomes based on the
presence of TILs in different types of cancer. We assumed that the
direction of prognostic influence of TILs would be the same in all
solid tumour types, but that only the magnitude of this effect might
differ between tumour locations and/or stage of disease. Therefore,
we felt it was justified not to focus on one particular tumour type.
METHODS
Search strategy
We designed a broad PubMed and Embase search, using the
following terms: prognosis[tw], prognos*[tw], mortality[tw],
surviv*[tw], survival[tw], disease free survival, disease specific
survival, progression free survival, tumor infiltrating lymphocyte*,
intratumoral lymphocyte*, intratumoural lymphocyte*, intra-
tumoural lymphocyte*, intra-tumoral lymphocyte*, TIL[tw],
cancer[tw], malignancy[tw], malignan*[tw], neoplasm*[tw],
tumor*[tw], tumour*[tw], carcinoma*[tw]. We used the following
MeSH terms: ‘prognosis’, ‘mortality’, ‘survival’, ‘survival analysis’,
‘disease-free survival’, ‘lymphocytes, tumor-infiltrating’, ‘CD4þ-
Positive T-Lymphocytes’, ‘CD8þ-Positive T-Lymphocytes’, ‘neo-
plasms’. Additionally, possible missing papers were searched in
reference lists of selected papers and related articles as suggested
by PubMed.
Inclusion criteria
We only included studies, in which the prognostic significance of
CD3þ, CD4þ, CD8þ, and FoxP3þ lymphocytes was examined,
including ratios between these subsets. These lymphocyte markers
were chosen based on the assumption that these were the most
frequently used markers. All papers in which only haematoxylin
and eosin stained slides were used, or which did not incorporate a
time-to-event survival analysis, were excluded. Similarly, immuno-
logical clinical trials were rejected, because active immunotherapy
aims to modify the presence or the composition of
T-lymphocyte subsets. We, however, were only interested in the
prognostic relevance of TILs in the naturally occurring immuno-
logical situation. Furthermore, we also excluded in vitro and
animal studies.
Only studies regarding intratumoural lymphocytes were
included. The analysis of lymphocytes in tumour stroma was an
exclusion criterion. This also applied to stromal lymphocytes
combined with intratumoural lymphocytes (e.g., ‘tumour and
surrounding stroma’). To be sure that the same definition of
‘intratumoural’ was used in all included papers, we excluded all
studies in that the lymphocyte location was not clearly specified.
We included studies in solid tumours of any kind. Haemato-
logical malignancies were excluded, because these are malignan-
cies of the immune cells themselves.
To increase the power of our analysis, it was decided to only
include larger studies with nX100 patients, to avoid publication
bias that might exist among small studies.
Finally, all included papers had to be published between January
2003 and February 2011 and written in English. In early 2003, the
landmark paper by Zhang et al was published (Zhang et al, 2003).
This paper subsequently inspired many authors to determine the
prognostic significance of TILs in many types of cancer, and
thereby formed a rational starting point for our literature search.
Figure 1 shows a flowchart of the study selection process. The
search yielded 2935 papers in Pubmed and 1026 papers in Embase,
584 of which were not found in Pubmed. Thus, 3519 unique papers
were found. With the inclusion criteria mentioned above, the full-
text version of 106 papers was reviewed. Of these papers, another
54 were excluded because they did not fit the inclusion criteria.
Specifically, four of these 54 were excluded because of the use of
the same cohorts. Zlobec et al (2007, 2008a,b), Lugli et al (2009),
and Baker et al (2007) all used (selections of) the same cohort.
One paper by Zlobec et al (2007) was selected based on the
reporting of hazard ratios and the use of the largest cohort.
Papers by Milne et al (2009) and Clarke et al (2009) also stem from
the same tissue microarray. As Milne et al did not report hazard
ratios, this paper was excluded, except in case of the FoxP3þ
staining, which was not reported by Clarke et al. Finally, the
cohorts used by Galon et al (2006) and Pages et al (2009) were the
same. Pages et al paper was excluded, as only Galon et al paper
enabled the estimation of hazard ratios (HRs) (see: Statistical
analysis). Thus, 52 papers were included in the systematic review
part of the study.
Data extraction
Data were extracted using a predefined form, recording: author,
journal, year of publication, tumour type, lymphocyte subsets,
location of lymphocytes, median follow-up time, scoring methods,
cut-offs for positive expression, number of TILs-low and TILs-high
patients, outcome of univariate and/or multivariate analysis
(including P-values, hazard ratios, and 95% confidence intervals)
and other major study outcomes.
Unless indicated, we only report outcomes from the whole
cohort included in these studies. Subgroup analyses are not
specifically mentioned. Some studies were entirely carried out in a
subgroup of patients, for instance only in advanced stage patients.
These studies are specified in the Supplementary Tables.
2935 records from PubMed
1026 records from Embase
442 duplicates removed
3413 abstracts excluded
54 full-text articles excluded
-  sample size too small (n=13)
-  unclear location of TIL (n=6)
-  only peritumoural or stromal
analysis (n=3)
-  overlapping cohorts (n=4)
-  letter to the editor (n=1)
-  no survival analysis (n=1)
-  Only reports ratio (n=4)
-  No HR and CI obtained (n=15)
Excluded from meta-analysis
-  only activation and inhibition
 markers (n=3)
-  only H&E slided evaluated (n=14)
-  combined analysis of tumour and
stroma (n=9)
3519 abstracts screened
106 of full-text articles assessed
for eligibility
52 studies included in
systematic review
33 studies included in
meta-analysis
Figure 1 Flowchart of study selection process.
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sThe results from univariate Cox regression, that is, HRs and 95%
confidence intervals (CIs), were used for meta-analysis. For all
lymphocyte ratios other than CD8/FoxP3, there were not enough
studies available to carry out meta-analysis. Therefore, all studies
that only reported only these lymphocyte ratios, and not the results
from the lymphocyte subsets on their own, were excluded from
meta-analysis (Hiraoka et al, 2006b; Kobayashi et al, 2007; Han
et al, 2008).
Thus, we attempted to carry out meta-analysis on 49 studies,
which requires HRs and 95% CIs from univariate Cox regression
analysis. Nine of these 49 papers reported HRs and 95% CIs for all
stainings (Sato et al, 2005; Gao et al, 2007; Nedergaard et al, 2007;
Siddiqui et al, 2007; Zlobec et al, 2007; Lee et al, 2008; Li et al,
2009; Shen et al, 2010; Zingg et al, 2010). Three papers only
reported some stainings (Jordanova et al, 2008; Clarke et al, 2009;
Sinicrope et al, 2009), and in two papers only stratified or
subgroup analyses were mentioned (Nosho et al, 2010; de Kruijf
et al, 2010). In all, 35 papers did not report any HRs and CIs for
progression or survival (Cho et al, 2003; Toomey et al, 2003;
Wakabayashi et al, 2003; Zhang et al, 2003; Chiba et al, 2004; Prall
et al, 2004; Baeten et al, 2006; Bates et al, 2006; Cai et al, 2006,
2009; Galon et al, 2006; Hiraoka et al, 2006a; Al Shibli et al, 2008;
Callahan et al, 2008; Heimberger et al, 2008; Kawai et al, 2008;
Perrone et al, 2008; Sasaki et al, 2008; Shah et al, 2008; Tomsova
et al, 2008; Adams et al, 2009; De Jong et al, 2009; Gobert et al,
2009; Jensen et al, 2009; Leffers et al, 2009; Milne et al, 2009;
Ruffini et al, 2009; Stumpf et al, 2009; Al Attar et al, 2010; Barnett
et al, 2010; Deschoolmeester et al, 2010; Kasajima et al, 2010;
Shimizu et al, 2010; Simpson et al, 2010; Sorbye et al, 2011). The
authors of 40 papers with (partially) missing data were contacted,
but we were unable to trace three authors (Cho et al, 2003;
Wakabayashi et al, 2003; Baeten et al, 2006). In all, 15 authors very
kindly sent us the requested data (Chiba et al, 2004; Prall et al,
2004; Bates et al, 2006; Hiraoka et al, 2006a; Jordanova et al, 2008;
Sasaki et al, 2008; Cai et al, 2009; Clarke et al, 2009; De Jong et al,
2009; Jensen et al, 2009; Leffers et al, 2009; Milne et al, 2009;
Ruffini et al, 2009; Barnett et al, 2010; Sorbye et al, 2011). For the
remaining studies, estimations of HRs and 95% CIs were
attempted using the spreadsheet provided by Tierney et al (2007.
This was successful in eight cases (Zhang et al, 2003; Galon et al,
2006; Al Shibli et al, 2008; Perrone et al, 2008; Tomsova et al, 2008;
Adams et al, 2009; Sinicrope et al, 2009; Kasajima et al, 2010). In
cases with partially missing data, the available data were used (de
Kruijf et al, 2010; Nosho et al, 2010). Finally, fifteen studies for that
no HRs and CIs could be obtained, were excluded from meta-
analysis and only included in the systematic review part of this
paper (Cho et al, 2003; Toomey et al, 2003; Wakabayashi et al,
2003; Baeten et al, 2006; Cai et al, 2006; Callahan et al, 2008;
Heimberger et al, 2008; Kawai et al, 2008; Shah et al, 2008; Gobert
et al, 2009; Stumpf et al, 2009; Al Attar et al, 2010; Deschoolmee-
ster et al, 2010; Shimizu et al, 2010; Simpson et al, 2010). Thus,
ultimately 34 out of 49 studies were included in the meta-analysis
part of this study.
Assessment of study quality
Study quality was assessed using the predefined form by De Graeff
(de Graeff et al, 2009), which was adapted from Hayes (Hayes et al,
1996) and McShane (McShane et al, 2005). Briefly, the following
criteria were scored: (1) Are in- and exclusion criteria defined? (2)
Is the study prospective or retrospective? (3) Are the clinical and
pathological characteristics of the patients sufficiently described?
(4) Is the method used sufficiently described? (5) Is the outcome
measure defined? (6) Is the follow-up time recorded? (7) Does the
study report the number of patients lost to follow-up or otherwise
unavailable for statistical analysis? (Supplementary Table 1). As
this quality score is not validated, we did not exclude studies based
on a low score.
Statistical analysis
All calculations were performed with HRs defined as the risk of
death or progression for high TILs vs low TILs tumours. In studies
that reported HRs for low TILs vs high TILs, the reciprocal of the
HRs and CIs was taken to calculate the results the other way
around.
Meta-analysis is generally carried out with the natural logarithm
of the HR and its standard error, to make the range of HRs
symmetrical. After log transformation, a HR of 0 becomes minus
infinity, a HR of 1 becomes 0, and a HR of infinity remains infinity
(Higgings and Green, 2009). We calculated the log hazard ratio and
associated standard errors using the spreadsheet provided by
Tierney et al (2007).
Next, meta-analysis was carried out with the DerSimonian Laird
model for random effects, using the inverse of variance as a
weighing factor. All analyses were stratified by T-lymphocyte
subset. The I
2 statistic was used to evaluate heterogeneity. A value
450% on the scale of 0–100% was considered to indicate
substantial heterogeneity between studies. Funnel plots were
constructed to assess publication and/or selection bias.
The studies in this systematic review and meta-analysis vary
widely with regard to methodology. We wondered whether these
differences would affect study outcomes. Additionally, we wanted
to identify sources of heterogeneity, which appeared in pooled
analyses. Therefore, stratified analyses were carried out for CD3þ
and CD8þ, because these subsets were investigated in the largest
number of studies. All stratified analyses were carried out with
overall survival only to increase uniformity. Differences between
strata were assessed using the test for subgroup differences in
Review Manager (The Cochrane Collaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark).
All analyses were carried out using SPSS version 16.0 (SPSS,
Chicago, IL, USA) and Review Manager version 5.0.
RESULTS
Study characteristics
The 52 studies had a median quality score of 5 out of 8 (range:
3–8) and consisted of a median of 160 patients (range: 100–1290),
with a median follow-up of 47 months (range: 20–228), and were
published in journals with a median impact factor of 5.07 (range:
1.15–47.05). All studies used immunohistochemistry as method
for detecting TILs.
Table 1 summarises some important study characteristics. Most
studies were carried out in ovarian cancer, but studies in colorectal
cancer (CRC) contained most patients. CD8þ was by far the most
popular lymphocyte marker, as it was quantified in 73.3% of
patients. Most studies used whole-tissue slides to evaluate TILs,
but studies in which tissue microarrays (TMAs) were used,
included more patients. This is consistent with the fact that TMAs
are especially suited for high-throughput analysis. Finally, count-
ing TILs in representative areas of tumour was more popular than
specifically selecting hotspots with highest infiltration rates.
Pooled analysis
We carried out meta-analysis under the assumption of homo-
geneity, stratified by T-lymphocyte subset. For CD3þ, a general
T-lymphocyte marker, the results are shown in Figure 2. The
pooled HR and CI for overall and progression-free survival are
very similar, both pointing to a survival advantage associated with
presence of TILs (HR 0.58, 95% CI of 0.43–0.78 for death, HR 0.53,
95% CI 0.39–0.73 for progression). Only two studies used disease-
specific survival, with opposing results. However, there is a
considerable degree of heterogeneity in the analyses, as well as
slight asymmetry in the funnel plots (Figure 5A). Eight studies
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scould not be included in meta-analysis, because no HRs and CIs
were reported (Supplementary Table 2, Toomey et al, 2003; Baeten
et al, 2006; Cai et al, 2006; Shah et al, 2008; Stumpf et al, 2009; Al
Attar et al, 2010; Deschoolmeester et al, 2010; Simpson et al, 2010).
Three studies found significant positive influence of CD3þ TILs
on overall survival (Al Attar et al, 2010), disease-specific survival
(Simpson et al, 2010), and disease-free survival (Cai et al, 2006),
but four found no effect on overall survival (Toomey et al, 2003;
Baeten et al, 2006; Shah et al, 2008; Stumpf et al, 2009). Of these
four, two did find that progression-free or disease-free survival
improved with CD3þ infiltration (Toomey et al, 2003; Stumpf
et al, 2009). The remaining study describes beneficial effects of
CD3þ TILs on disease-free survival, but not on overall survival
(Deschoolmeester et al, 2010).
For CD8þ, 23 studies were included in meta-analysis. The
presence of CD8þ results in prognostic advantages for all survival
endpoints tested (Figure 3). Again, there was a considerable
amount of heterogeneity present, but the funnel plot was more
symmetric (Figure 5B). Of the eight studies that could not be
included in meta-analysis, seven reported improved overall
survival (Cho et al, 2003; Baeten et al, 2006; Cai et al, 2006;
Callahan et al, 2008; Kawai et al, 2008; Stumpf et al, 2009;
Deschoolmeester et al, 2010). One study found a negative effect of
CD8þ TIL on survival, but this did not reach statistical
significance in multivariate analysis (Wakabayashi et al, 2003)
(Supplementary Table 4).
Meta-analysis of the six studies reporting overall survival in
CD4þ revealed a pooled HR of 0.82, with a 95% CI of 0.69–0.98,
which is statistically significant (P¼0.03, data not shown).
Heterogeneity was 0%. Progression-free survival (Gao et al, 2007;
Nedergaard et al, 2007; Li et al, 2009) and disease-specific survival
(Al Shibli et al, 2008; Sorbye et al, 2011) were not influenced by
CD4þ TILs in pooled analysis (data not shown). Four papers were
Study or subgroup
Overall survival
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Figure 2 Forest plots of studies on CD3þ TILs. Hazard ratios and 95% confidence intervals from individual studies are depicted as squares and horizontal
lines, respectively. The pooled estimate is shown as a diamond shape, where the center represents the pooled HR and the horizontal borders represent the
95% CI. Hazard ratios are defined as high CD3 vs low CD3 counts, therefore a hazard ratio o1 represents a lower risk of death or progression associated
with high CD3 counts.
Table 1 Characteristics of the included studies
Number of studies Number of patients
Types of cancer
Ovarian 14 (26.9%) 2574 (20.7%)
Colorectal 10 (19.2%) 3984 (32.0%)
Lung 7 (13.5%) 2328 (18.7%)
Hepatocellular 5 (9.6%) 909 (7.3%)
Renal cell 3 (5.8%) 416 (3.3%)
Other 13 (25.0%) 2234 (18.0%)
Types of lymphocytes
a
CD3+ 22 (20.0%) 4678 (37.6%)
CD4+ 15 (13.6%) 2707 (21.8%)
CD8+ 32 (29.1%) 9126 (73.3%)
FoxP3+ 23 (20.9%) 4786 (38.5%)
Ratios 18 (16.3%) 3017 (24.2%)
Type of tissue analysed
Tissue microarray 20 (38.5%) 6487 (52.1%)
Whole-tissue slides 32 (61.5%) 5958 (47.9%)
Areas of scoring
Hotspots 15 (28.8%) 2651 (21.3%)
Representative areas 37 (71.2%) 9794 (78.7%)
aTotal percentage is 4100%, as most studies included 41 lymphocyte subset,
percentage of total numbers of studies and total number of patients included.
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sexcluded from pooled analysis because Cox regression analysis was
not performed. One of these report improved overall survival
(Cho et al, 2003), but three other papers do not find a statistical
significant effect of CD4þ TILs (Wakabayashi et al, 2003;
Jordanova et al, 2008; Stumpf et al, 2009) (Supplementary Table 3).
FoxP3þ is a relatively selective Treg marker (Hori et al, 2003)
and was used in all 22 studies we included. Surprisingly, meta-
analysis on 18 of these showed no statistically significant impact
on overall, disease-specific, or progression-free survival (Figure 4).
Heterogeneity was present, and the funnel plot was slightly
asymmetric (Figure 5C). Four studies were excluded from meta-
analysis, two of these found no prognostic significance of Treg
(Shah et al, 2008; Gobert et al, 2009), whereas the remaining
studies showed that Treg infiltration was associated with improved
survival (Heimberger et al, 2008) and reduced relapse-free survival
(Shimizu et al, 2010) (Supplementary Table 5).
Six studies have examined both CD4þ and FoxP3þ (Sato et al,
2005; Gao et al, 2007; Jordanova et al, 2008; Li et al, 2009; Shen
et al, 2010; Zingg et al, 2010). Jordanova et al (2008) and Gao et al
(2007) et al found a no effect of CD4þ, but a negative effect of
FoxP3þ in univariate analysis in cervical and hepatocellular
cancer, respectively. However, only Jordanova carried out
multivariate analysis, in which this effect did not hold. The
remaining studies observe a prognostic effect of neither CD4þ
nor FoxP3þ in esophageal, gastric, ovarian, and renal cell cancer
(Sato et al, 2005; Li et al, 2009; Shen et al, 2010; Zingg et al, 2010).
Stratified analysis
In case of CD3þ, the pooled results from the seven smallest
studies were strongly significant, whereas this was not the case
with four larger studies (Table 2). Similarly, studies with a shorter
follow-up and high quality score showed a statistically significant
pooled result, whereas this was not the case for those with a long
follow-up or a low quality score. However, follow-up duration was
not reported in all studies. Interestingly, the choice of tissue type
also seemed to be influential. Using whole-tissue slides as opposed
to a TMA resulted in a lower pooled HR. Stratifying for tumour
type was not entirely feasible, because of insufficient studies in
similar cancer types. However, when comparing the two most
popular malignancies, there were no significant differences
between results in ovarian and colorectal cancer. Overall,
heterogeneity was not decreased by performing stratified analysis,
and is therefore from thus far unknown origins.
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Figure 3 Forest plots of studies on CD8þ TILs. Hazard ratios and 95% confidence intervals for death or progression associated with high vs low CD8
counts.
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infiltration was more pronounced in studies with fewer patients
and shorter median follow-up time. Again, ovarian and colorectal
cancers were the most frequently used types of cancer, both with
similar outcomes. Heterogeneity seemed to be especially affected
by study size and follow-up duration, but the latter is probably
influenced by the exclusion from this analysis of four studies,
which did not report follow up.
Ratios between T-lymphocyte subsets
Relatively few studies incorporated T-lymphocyte ratios (Supple-
mentary Table 6). Moreover, the use of different survival outcomes
(overall, disease-specific, disease-free, and relapse-free survival)
decreased the potential for pooled analysis even further. Therefore,
pooled analysis was only possible for the CD8/FoxP3 ratio.
Pooled analysis for the six studies reporting overall survival
based on CD8/FoxP3 ratios was strongly significant with relatively
low heterogeneity (HR 0.48, 95% CI 0.34–0.68, Po0.0001, I
2¼49%)
(Sato et al, 2005; Jordanova et al, 2008; Cai et al, 2009; Barnett et al,
2010; Shen et al, 2010; Zingg et al, 2010). Furthermore, two studies
report positive effects of a high CD8/FoxP3 ratio on disease-
specific (De Jong et al, 2009; Leffers et al, 2009) and progression-
free survival (Cai et al, 2009; De Jong et al, 2009).
In three studies, the CD3þ/CD8þ ratio was used, but each
used a different interpretation of this ratio. Han et al (2008) found
an independent positive effect of either CD3þ or CD8þ
compared with no CD3þ or CD8þ in ovarian cancer. In gastric
cancer, Lee et al (2008) observed that high numbers of both CD3þ
and CD8þ are favorable compared with low numbers of both cell
types. Finally, Kobayashi et al (2007) found that high numbers of
CD8þ compared with CD3þ was not a prognostic factor in
hepatocellular cancer. Naturally, for this ratio it is important to
keep in mind that most CD8þ cytotoxic lymphocytes are also
CD3þ.
The CD8þ/CD4þ ratio was used in three studies (Sato et al,
2005; Jordanova et al, 2008; Zingg et al, 2010), and found to be a
positive prognostic predictor in one of these (Sato et al, 2005).
Importantly, the CD4þ component also contains Treg. Thus, this
ratio is more difficult to interpret than the CD8þ/FoxP3þ ratio,
as the CD4þ population can be very mixed.
The FoxP3þ/CD3þ and FoxP3þ/CD4þ ratio were used in
one (Sinicrope et al, 2009) and two (Hiraoka et al, 2006b;
Kobayashi et al, 2007) studies, respectively. All three studies found a
negative prognostic effect associated with FoxP3þ preponderance.
DISCUSSION
Quantifying TILs by histopathology is a frequently used approach
to gain insight in the immunological activity against tumours. In
this systematic review and meta-analysis, we analysed larger
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Figure 4 Forest plots of studies on FoxP3þ TILs. Hazard ratios and 95% confidence intervals for death or progression associated with high vs low FoxP3
counts.
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sstudies of recent years to determine which similarities and
differences exist between their results.
CD3þ and CD8þ TILs turned out to have a positive effect on
prognosis in meta-analysis, with HRs of 0.58 (95% CI 0.43–0.78)
and 0.71 (95% CI 0.62–0.82), respectively, for death from all
causes. CD4þ TILs were associated with a slightly improved
overall survival (HR 0.82, 95% CI 0.69–0.98), but its FoxP3þ
regulatory subset not associated with overall survival (HR 1.19,
95% CI 0.84–1.67). All in all, these HRs represent statistically
significant, but not dramatic differences in survival. The CD8/
FoxP3 ratio produced a more impressive HR (risk of death: HR
0.48, 95% CI 0.34–0.68) but was used in relatively few studies.
These results underline the need to examine FoxP3 and CD8
together.
We carried out this meta-analysis assuming that the prognostic
effect of TILs would not differ greatly between types of cancer. We
considered it unlikely that TILs infiltration strongly improves
prognosis in one type of cancer, but has the complete opposite
effect in another. However, clinicopathological factors might affect
the impact of TILs on prognosis, that is, HRs moving closer to (but
not crossing) 1 in high stage or grade. We attempted to test this
hypothesis post hoc in stratified analysis. These analyses were
limited by the fact that sufficient numbers of studies were only
available for ovarian and colorectal cancer. For these tumour
types, we found no significant differences between pooled
outcomes. Moreover, heterogeneity was not clearly affected. This
indicates that the prognostic effects of CD3þ and CD8þ TILs are
similar in ovarian and colorectal cancer and that heterogeneity in
pooled analysis was caused by factors other than tumour type.
Furthermore, stratified analysis provided some hints that
methodological aspects such as sample size and follow-up time
may have influenced outcomes of studies on CD3þ and CD8þ
TILs. For CD3þ and CD8þ TILs, smaller studies produced more
dramatic HRs than larger studies. Additionally, studies with a
longer follow-up time were less likely to produce statistically
significant results. Unfortunately, as not all studies report median
follow-up times, these results are tentative. Differences in
significant results based on sample size or follow up time may
be caused by publication bias. This can be detected by funnel plots,
but these are relatively crude and have a tendency for false
positivity. In our case, the funnel plots should be interpreted with
caution as the number of studies in our meta-analysis is relatively
small and consist of different populations (Lau et al, 2006). This
means that the asymmetry may not just be caused by publication
or selection bias, but also by inherent differences in study
populations (Lau et al, 2006). Thus, although some asymmetry
seemed to be present, we cannot conclude with certainty whether
publication bias was an issue.
In addition to the factors we tested in subgroup analysis, the
determination of cutoff points also differed widely. Some studies
use percentiles, tertiles or the median, whereas others use absence
vs presence, the minimal P-value approach, or do not report a
cutoff point at all. All studies used immunohistochemistry, which
is notorious for its variability due to factors related to staining
protocols or tissue fixation techniques. It is an attractive technique
to use as primary screening, but the next step should be to validate
the results in other models.
These results raise the question whether biology or methodology
is the source of the observed prognostic effects of TILs on survival.
Biological support can be gained from studies into T-lymphocyte
kinetics, which offer a more detailed perspective. It has been
shown that immune cells can proliferate in vitro in response to
tumour-specific antigens, and that the influx of immune cells into
a tumour results in the induction of an inflammatory microenviron-
ment (reviewed in Kim et al, 2007; Finn, 2008). Murine studies also
demonstrated the potency of the immune system, when adoptive
transfer of tumour-specific CD8þ T-lymphocytes resulted in
complete eradication or regression of established tumours
(Vierboom et al, 1997; Palmer et al, 2004; Ruttinger et al, 2004;
Wall et al, 2007). Also, the increase in cancer risk seen after solid
organ transplantation, when immunosuppressive drugs are used,
suggests a prominent role for immune surveillance (Kim et al,
2007).
Nonetheless, several biological mechanisms may at the same
time prevent antitumour responses of TILs. For instance,
lymphocytes present in the tumour might not always be active,
due to immune escape or tolerance. Alternatively, the immune
response may be skewed towards relatively ineffective Th2 or Treg
responses. Tumour-infiltrating lymphocytes may also be properly
activated, but simply out of their league because of the speed of
tumour growth. However, these hypotheses cannot be fully
investigated in immunohistochemical studies. Some attempts at a
more functional perspective have been made by staining for
activation markers on lymphocytes such as Granzyme-B (Oshikiri
et al, 2003; Gao et al, 2007), CD25 (Ladanyi et al, 2004), OX40
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s(CD134) (Ladanyi et al, 2004) and CD69 (Hillen et al, 2008), or
inhibiting co-stimulatory molecules such as PD-1 (Thompson et al,
2007) and its ligand B7-H1 (Thompson et al, 2005; Boorjian et al,
2008). These observations may provide a more precise view, but
relatively few studies have used these markers. Moreover, more
in vitro and animal-based studies are still required to understand
the exact dynamics.
Most likely, methodological aspects have had an effect on the
magnitude of the effect seen in some studies, or on their likelihood
to be published, but they are not solely responsible for study
outcome. This is especially likely in the presence of evidence from
in vitro and mouse studies, in which T lymphocytes are not
evaluated on a statistical, but on a mechanical level. Nonetheless,
the importance of differences in methodology and/or reporting
was highlighted by Altman et al (1995) and McShane et al (2005).
They proposed guidelines for the reporting of prognostic marker
studies, to encourage transparent reporting and to assist the reader
in judging study quality (McShane et al, 2005). We used these
guidelines in an adapted form to assess study quality (de Graeff
et al, 2009). Using these criteria, we observed that 19 out of 52
studies (36.5%) failed to adequately report follow-up time and 22
out of 52 (42.3%) not report clear in- and exclusion criteria.
Importantly, only one of the included studies reached the
maximum score of 8 points (Nosho et al, 2010), mainly because
all but two studies (Sinicrope et al, 2009; Nosho et al, 2010) were
retrospective. Hoppin et al (2002) described nicely how retro-
spective tissue-based studies can lead to bias, as the availability of
tumour specimens in pathology archives may depend on a wide
variety of factors such as patient age, tumour size, tumour grade
and hospital, in which the patient was diagnosed. An alternative to
prospective studies is the structured collection of specimens from
all patients and all hospitals in a region, and a very thorough
description of patient demographics to analyse potential bias
afterwards.
Our systematic review has some limitations of its own, inherent
to its design. We included a very heterogeneous group of studies,
consisting of many different types of cancer, different patient
selection criteria and different types of methodology. As men-
tioned above, we felt it was justified to pool them anyway, because
we expected the biological functions of TILs to be independent of
tumour type. Nonetheless, the effect size that TILs might have in
terms of prolonging survival, is undoubtedly related to clinico-
pathological factors such as differentiation grade. These interac-
tions can be corrected for in multivariate analyses. However,
multivariate analysis is not suitable for pooled analysis, because
the covariates used in multivariate analysis vary between studies,
and because their outcomes cannot be estimated based on other
data in the paper.
Another limitation is that many studies had to be excluded from
meta-analysis because they did not report HRs and CIs, but only
Kaplan–Meier curves and log-rank tests. Only 9 out of 49 (18.4%)
reported HRs and CIs for some or all stainings. We managed to
reduce the missing data by contacting authors, and by estimating
outcome with the help of a spreadsheet (Tierney et al, 2007). The
latter may have introduced some imprecision, but we felt this was a
risk worth taking in view of the alternative, that is, excluding the
studies. This highlights the importance of a uniform reporting of
study outcomes and follow-up time.
A final limitation is our use of strict inclusion criteria, which
resulted in exclusion of smaller studies. This was intended to
eliminate studies with little precision, but thereby also reduced the
number of studies included in this meta-analysis because small
studies are published relatively frequently. Hence, stratified
analysis was not possible for all TIL subsets. Moreover, stratified
analyses were performed in relatively limited numbers of studies.
The results from these analyses should therefore not be interpreted
strictly based on their numerical outcome, but rather as general
suggestions for designing future studies.
Table 2 Summarised hazard ratios
Number of
studies
Number of
patients
Pooled HR
(95% CI) I
2 value (%) P-value
P-value
differences
a
CD3+
Smallest studies
b 7 1039 0.48 (0.33–0.69) 72 o0.0001 o0.00001
Largest studies
c 4 1985 0.76 (0.55–1.07) 86 0.11
Median follow-up o4 years 5 918 0.53 (0.36–0.78) 65 0.001 o0.000001
Median follow-up 44 years 4 1808 0.83 (0.66–1.04) 59 0.11
Quality score p5 4 741 0.58 (0.30–1.13) 89 0.11 0.11
Quality score 45 7 2301 0.58 (0.41–0.82) 86 0.002
Tissue microarray 5 2223 0.70 (0.51–0.97) 85 0.03 o0.00001
Whole-tissue slides 6 819 0.48 (0.31–0.75) 77 0.001
Hotspots scored 4 671 0.62 (0.37–1.04) 79 0.07 0.73
Representative areas scored 7 2371 0.55 (0.37–0.83) 89 0.004
Ovarian cancer 5 1053 0.53 (0.28–1.01) 92 0.05 0.25
Colorectal cancer 3 1319 0.64 (0.37–1.10) 84 0.11
CD8+
Smallest studies
d 12 2319 0.66 (0.53–0.81) 59 0.0001 0.003
Largest studies
e 4 3740 0.82 (0.75–0.91) 0 o0.0001
Median follow-up o4 years 6 1322 0.53 (0.45–0.62) 0 o0.00001 0.0003
Median follow-up 44 years 9 2539 0.76 (0.64–0.90) 48 0.002
Quality score p5 7 2348 0.74 (0.61–0.91) 48 0.004 0.46
Quality score 45 9 3693 0.69 (0.56–0.86) 70 0.0006
Tissue microarray 9 3926 0.71 (0.60–0.85) 61 0.0001 0.53
Whole-tissue slides 7 2133 0.72 (0.55–0.95) 66 0.02
Hotspots scored 5 893 0.75 (0.59–0.97) 37 0.03 0.98
Representative areas scored 11 5166 0.70 (0.58–0.83) 69 o0.0001
Ovarian cancer 4 983 0.69 (0.54–0.88) 49 0.003 0.45
Colorectal cancer 4 2582 0.62 (0.44–0.88) 81 0.007
Abbreviations: CIs¼confidence intervals; HRs¼hazard ratios. All analyses were carried out for overall survival only. Median follow-up was not available for all studies.
aP-values
for differences between pairs, bold indicating whether there are statistically significant differences between pooled results from, for instance, small and large studies.
bn¼100–
220.
cn¼302–786.
dn¼109–359.
en¼500–1290.
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sIn conclusion, we found evidence that TILs moderately influence
prognosis, but this influence is more pronounced in studies
incorporating lymphocyte ratios. However, the exact magnitude
of TILs on prognosis remains somewhat mysterious due to
methodological factors. Improving study quality is an essential
step toward uncovering the real clinical relevance of TILs.
Moreover, just quantifying TILs may not take the dynamics
of the tumour microenvironment into account. Any future studies
should have a very strict design, with large sample sizes to increase
statistical power, a uniform way of analyzing survival outcomes,
and a long and specified follow-up period.
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